Q-omics provides the consensus-scored PLSCR1 profile across patient tissues and cancer cell-line models. PLSCR1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PLSCR1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PLSCR1 RNA expression shows 19,278 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, HNSC, and THYM as cancer lineages where PLSCR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLSCR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLSCR1 survival associations across molecular data types. PLSCR1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLSCR1 RNA expression–survival associations across cancer types. High PLSCR1 expression shows unfavorable associations in UCEC, ACC, LGG, LUAD and PAAD, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PLSCR1 RNA expression.
This table summarizes PLSCR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLSCR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLSCR1 shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, BLCA, CHOL and ESCA. The HNSC box plot shows higher PLSCR1 RNA expression in tumor versus normal tissue (log2 FC = +1.075, t-test p < 0.001).
This table shows molecular features associated with PLSCR1 in patient tissues and cancer cell lines. In patient samples, PLSCR1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLSCR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
